Umoja Biopharma has announced the closing of an oversubscribed $100m Series C financing round, which will enable the company to progress its in vivo chimeric antigen receptor (CAR)-T cell therapy pipeline.

Double Point Ventures and DCVC Bio jointly led the round, with participation from existing and new investors including ARK Invest, MPM Capital, Cormorant Asset Management, Qiming Venture Partners USA and Alexandria Venture Investments.

Proceeds from the round will help propel the advancement of the company’s lead CD22 UB-VV400 programme in several oncology and autoimmune clinical trials.

Umoja Biopharma co-founder and CEO Andrew Scharenberg stated: “We are pleased to announce the closing of our Series C financing with tremendous support from both new and existing investors who recognise Umoja’s potential to develop the industry’s first in vivo CAR T cell generating therapies — all in the hopes of increasing effectiveness, reducing barriers and expanding access to CAR T cell therapies.”

Senior adviser at Double Point Ventures, Dr Campbell Murray has been appointed as a new member of Umoja’s board of directors. Dr Phil Low of Purdue University will serve as chair of the company’s scientific advisory board and has been transitioned to the role of board observer.

Murray said: “It is an honour to co-lead this transformative investment round and to join Umoja’s board of directors.

GMP mRNA
Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

AAV Packaging Services

We have developed a series of proprietary technologies that greatly improve AAV production outcomes including titer, purity, potency, and consistency.

READ MORE

Off-the-Shelf AAV Products

We offer a library of carefully designed and pre-stocked AAV vectors for a wide variety of experimental needs.

READ MORE